This MB has some very well informed and positve posters. My sense is we may have the technology here to help a lot of sick people, or to at least present a quality of life improvement opportunity. Hope you all prosper with your choice. Do not underestimate the power of prayer.
What do you expect in the Obama nation where pot is legal, men marry men, women have tatoos, men wear ear rings, 50% of births are one parent, abortion is free and expected, zero educational credibility, politicians are total frauds, 47% of the population pays no taxes, being honest is laughed at, not paying your bills is modeled by the government, phones are given by tax payers to every drug adict, punk and welfare momy...you get the idea. Its all good.
Excellent observation as it talks to the context we are investing in here. The dynamics of this situation (IMO) will drive investment and technology decisions almost on a daily basis. Safe and effective tests will drive monitors and controls ...and we can all figure out the rest.
seems to be a recycle move, will turn around
Chris..these are what I would call an identification(excellent) list of things we know about but do not understand the consequnces of. Dr. Peter senge , "The fifth Discipline" has worked this dynamics maodel to some degree. This, IMO, is the most exciteing aspect for AMBS stock holders. Whatever the future brings from clinicals and other sources is an unknown. We do not know, what we do not know about these links. At this point, constrained by whjat we know we can say it looks positve, at least.
don't agree with the 'no catalyst' comment until 2015. There are a myriad of catalysts that we know and many we don't, including but not limited to: Lympro data, Lympro partner/launch, diabetes/wolfram data, Myocardial data, other data, another orphan announcement, TBI summit, TBI product development?, Grants, maintenance of share price above .10 to receive $5M cash, P2 in-license, MANF strategy overview, partner license for MANF with upfront cash?, IND submission with a MANF partner, micro cap institutional investor prior to uplist, uplist to national exchange, more institutional investors, BUY ratings, etc. So, lots of catalysts. I could see selling a small portion to recoup investment on a nice Lympro partner pop in share price, but I will be right back in buying more and getting free shares with a modest pull back. Less
All, I very much appreciate the thread and valued concept sharing. I see another option. We do not know what we do not know. As new information develops by trials and clinical evaluations won't the field of possibilites explode? We have the best people WW waiting for a greakthrough which could present itself at any time. IMO R/S could be a non issue , medical science may dictate growth.
"Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfoling-related apoptosis. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders" from a recent PR. Just in case ...all the best...when I day dream I wonder if this can help all the kids who need treatment for brain disorders.
OK...well if that happens as you predict you are herebye OFFICIALLY AUTHORIZED to bo buy yourself a beer and relax AND...pat yourself on the back.
ZURICH (Reuters) - Swiss drugmaker Roche has found an efficient way for complex antibody drugs to reach and penetrate the brain, raising the possibility of more effective treatments for diseases such as Alzheimer's.
The innovative brain shuttle technology, which has so far been tested in mice, can cross the blood-brain barrier that has been a key obstacle for researchers working on neurological drugs because it acts as a seal against large molecules such as antibodies.
Alzheimer's is a fatal brain-wasting disease that affects 44 million people worldwide, with the number set to triple by 2050, campaign group Alzheimer's Disease International says.
Although there is still no treatment that can effectively modify the disease or slow its progression, a number of companies - including Roche, Eli Lilly, Merck & Co and Johnson & Johnson - are pursuing a variety of approaches to get to the root cause.
It is proving an uphill battle. Over the past 15 years more than 100 experimental Alzheimer's drugs have failed in tests. Industry analysts believe that the prize for a truly effective drug could be a market worth $10 billion in annual sales.
Roche's new technology works by hijacking a natural transport mechanism called receptor-mediated transcytosis, which is normally used by the body to transfer proteins inside the brain.
"We have basically designed this module, called shuttle, that binds to this transport mechanism and shuttles a cargo inside the brain," Luca Santarelli, Roche's head of neuroscience, ophthalmology and rare diseases, said in a telephone interview.
Results of a study published in the journal Neuron on Wednesday found the technology helped to increase the concentration of antibodies in the brains of mice, reducing the amount of amyloid plaque, which is a hallmark of Alzheimer's.
Roche tested a precursor of its experimental Alzheimer's drug gantenerumab in the pre-clinical trials. The amount of antibody that penetrated the brain
Agree. IMO, the SP will vary as function of learning. The good news is leadership has networked the best scientific resource bases available WW. We currently do not know, what we do not know, but we have the knowledge to apply new learnings for validation. As facts unfold (if it works, as Gerald has said) our envelope will change. There will either be an explosion of ideas, proofs and clinical validations or there will not be. Sooner is better.
Have had similar experiences. I am in as big as I can dare around 0.047. My gut (on balance) with AMBS is based on credible leaders doing credible work and the leadership impact of the science , which has to date not been overstated nor has it been debunked. (To the extent I am qualifed to judge). The load of dealing with regulatory bodies will either be nmanged with the benefit of anticipated results or it will not be , in which case AMBS will get swallowed. My sense is the product development speculation on cause/effect impact to SP is overly cautious by factors of 10+. It should be obvious when/if this happens. All the best.